Marizyme Inc.

Marizyme, Inc. (OTC: MRZM) is a biopharmaceutical company focused on the development of enzyme-based cardiovascular therapies, with its lead program targeting the development of a treatment for cardiovascular disease using proprietary enzyme technology derived from marine sources. According to its website at marizyme.com, the company is developing Gly-marizyme — a proprietary enzyme formulation derived from marine organisms — as a potential treatment for cardiovascular conditions including deep vein thrombosis and other thromboembolic conditions where clot dissolution and prevention of recurrent thrombotic events represents a significant clinical need. Marizyme's enzyme-based therapeutic approach draws on the distinctive biochemical properties of marine-derived enzymes that may offer advantages over conventional thrombolytic drugs in terms of selectivity, stability, or safety profile.

Marizyme's drug development programs, described at marizyme.com, focus on the preclinical and clinical development of its marine enzyme-derived therapeutic candidate through the regulatory approval process, conducting the in vitro, in vivo, and clinical studies required to demonstrate the safety and efficacy of Gly-marizyme in cardiovascular and thrombotic disease applications. The company's research approach combines pharmaceutical sciences expertise with knowledge of marine biochemistry and enzyme pharmacology to advance its lead program and evaluate potential additional applications of its marine enzyme technology platform in other cardiovascular and related disease states. Marizyme's cardiovascular disease focus addresses a major global health challenge where effective, safe treatments for thrombotic conditions represent substantial unmet medical and commercial opportunities.

Marizyme is a development-stage biopharmaceutical company pursuing the clinical and regulatory development of its marine enzyme-based cardiovascular therapeutic candidates within the resource constraints typical of small-cap pharmaceutical development companies. According to marizyme.com, the company is advancing its drug development programs through strategic partnerships, research collaborations, and capital markets access designed to fund the preclinical and clinical activities required to progress its lead program toward regulatory review. Marizyme's combination of marine-derived enzyme therapeutic technology, cardiovascular disease application focus, OTC-listed public company structure, and drug development stage positioning provides investors with exposure to a development-stage biopharmaceutical company pursuing a novel enzyme-based approach to cardiovascular disease treatment.